3.00 |
Welcome of the Chairs
Alain TAÏEB (Bordeaux, France) Kyu-Han KIM (Seoul, South-Korea) Peter SCHMID-GRENDELMEIER (Zurich, Switzerland)
|
|
3.05 |
Introductory lecture
AD and COVID-19: lessons from the SECURE-AD registry and beyond
Carsten FLOHR (London, United Kingdom)
|
view ➜
|
|
|
|
3.20 4.20 |
SESSION 1
New systemic treatments
Moderators:
Alain TAÏEB
Andreas WOLLENBERG (Munich, Germany)
|
|
|
Dupilumab: long term single center experience in Japan
Yoko KATAOKA (Osaka, Japan)
|
view ➜
|
|
Dupilumab: paradoxical reactions
Dirk Jan HIJNEN (Rotterdam, The Netherlands)
|
view ➜
|
|
Efficacy and safety of tralokinumab monotherapy in adult patients with moderate-to-severe atopic dermatitis: Results from two 52- week-phase 3 trials (ecztra 1 andecztra 2)
Eric L. SIMPSON (Portland, USA)
|
view ➜
|
|
Abrocitinib treatment in adolescents and adults with moderate-to-severe atopic dermatitis: Early pruritus responses from phase 3 trials jade mono-1 and jade mono-2
Jonathan SILVERBERG (Chicago, USA)
|
view ➜
|
|
Relationships between clinical response endpoints and other outcome measures: data from the updacitinib atopic dermatitis phase 2B trial
Kristian REICH (Hamburg, Germany)
|
view ➜
|
|
Panel Discussion
Moderators, Speakers, Amy S. PALLER (Chicago, USA) / Lisa BECK (Rochester, USA) / Emma GUTTMAN (New York, USA) / Kyu-Han KIM
|
|
|
|
|
4.20 |
COFFEE BREAK
Bring your own 😉
|
|
|
|
|
4.30 5.25 |
SESSION 2 New fields in AD: big data mining, AD in sub-Saharan Africa, neuroinflammation
Moderators: Peter SCHMID-GRENDELMEIER Johannes RING (Munich, Germany) Roberto TAKAOKA (Sao Paulo, Brasil) Norito KATOH (Kyoto, Japan)
|
|
|
Korean National Health insurance AD data
Jiyoung AHN (Seoul, South Korea)
|
view ➜
|
|
Teledermatology and AD in Subsaharan Africa
Garba MAHAMADOU (Lomé, Togo)
|
view ➜
|
|
Atopic dermatitis in Antananarivo, Madagascar
Benja RAPELANORO (Antanarivo, Madagascar)
|
view ➜
|
|
Neuroimmunology of atopic dermatitis
Martin STEINHOFF (Doha, QATAR)
|
view ➜
|
|
Panel Discussion
Speakers and moderators together
|
|
|
|
|
5.25 |
SUMMARY / FINAL REMARKS
Alain TAÏEB
|
|